Barclays’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Barclays’s Portfolio BSX.PRA Stock Details BSX.PRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-848	Closed	-$103K	–	5296
2023 Q1	$103K	Sell	848 -17,674	-95%	-$2.03M	﹤0.01%	4162
2022 Q4	$2.13M	Buy	18,522 +10,900	+143%	+$1.2M	﹤0.01%	2225
2022 Q3	$771K	Buy	+7,622	New	+$806K	﹤0.01%	2408

Other funds holding BSX.PRA

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Barclays's BSX.PRA Position: Q2 2023 in Review

Barclays sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 848 shares — an estimated $103K sold.

Barclays first reported a position in BSX.PRA in Q3 2022 and held it in 3 quarters. The position peaked at $2.13M in Q4 2022. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.

Barclays reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
Barclays sold 848 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $103K.
Barclays first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q3 2022 and held it in 3 quarters.
Barclays's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $2.13M in Q4 2022.
1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.